New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNY;BMY;MRK;JNJ;NVS;ABT;CELG;PFE;SHPG;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 8, 2014
08:11 EDTMRKCubist volatility elevated into Merck acquiring for $8.4B in cash
Subscribe for More Information
08:08 EDTMRKMerck says about $9.5B of debt to be issued related to Cubist deal
Subscribe for More Information
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:35 EDTMRKAdvaxis reports FDA acceptance of IND application for ADXS-PSA combination trial
Subscribe for More Information
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
07:13 EDTMRKMerck to host conference call
Subscribe for More Information
07:01 EDTMRKMerck to acquire Cubist for $102 per share in cash, or $9.5B
Subscribe for More Information
07:00 EDTMRKMerck to acquire Cubist for $102 per share in cash
Subscribe for More Information
05:53 EDTBMYStocks with implied volatility movement; BSX BMY
Subscribe for More Information
05:42 EDTNVSSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
December 7, 2014
16:40 EDTCELGAgios announces new data from Ongoing Phase 1 trial of AG-221
Subscribe for More Information
16:29 EDTMRKMerck in discussions to buy Cubist for $7B, Bloomberg reports
Subscribe for More Information
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
14:10 EDTBMY, CELGAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:16 EDTCELGCelgene, Acceleron announced data from luspatercept phase 2 clinical trial
Subscribe for More Information
13:06 EDTBMYBMY announces positive results in Phase 1b trial evaluating Opdivo
Subscribe for More Information
12:58 EDTMRKMerck presents KEYTRUDA data at ASH
Subscribe for More Information
December 6, 2014
09:28 EDTCELGCelgene to hold an analyst and investor event
Analyst and Investor Event being held in conjunction with the American Society of Hematology's 56th Annual Meeting in San Francisco on December 7 at 11 pm. Webcast Link
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use